MX2020004837A - Inhibidores de la vía de adenosina para el tratamiento del cáncer. - Google Patents

Inhibidores de la vía de adenosina para el tratamiento del cáncer.

Info

Publication number
MX2020004837A
MX2020004837A MX2020004837A MX2020004837A MX2020004837A MX 2020004837 A MX2020004837 A MX 2020004837A MX 2020004837 A MX2020004837 A MX 2020004837A MX 2020004837 A MX2020004837 A MX 2020004837A MX 2020004837 A MX2020004837 A MX 2020004837A
Authority
MX
Mexico
Prior art keywords
inhibitors
cancer
treatment
adenosine pathway
adenosine
Prior art date
Application number
MX2020004837A
Other languages
English (en)
Inventor
Richard A Miller
Andrew Hotson
Ian Mccaffery
Original Assignee
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc filed Critical Corvus Pharmaceuticals Inc
Publication of MX2020004837A publication Critical patent/MX2020004837A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Ecology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proporcionan en la presente, entre otros, los métodos para tratar el cáncer en sujetos que expresan niveles elevados de receptores A2A de adenosina, y opcionalmente que expresan niveles elevados de CD73 y/o PD-L1, mediante la administración de inhibidores de la vía de adenosina.
MX2020004837A 2017-11-06 2018-11-06 Inhibidores de la vía de adenosina para el tratamiento del cáncer. MX2020004837A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762582246P 2017-11-06 2017-11-06
PCT/US2018/059480 WO2019090347A1 (en) 2017-11-06 2018-11-06 Adenosine pathway inhibitors for cancer treatment

Publications (1)

Publication Number Publication Date
MX2020004837A true MX2020004837A (es) 2020-08-13

Family

ID=66332406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004837A MX2020004837A (es) 2017-11-06 2018-11-06 Inhibidores de la vía de adenosina para el tratamiento del cáncer.

Country Status (10)

Country Link
US (1) US20210008206A1 (es)
EP (1) EP3706753A4 (es)
JP (1) JP2021502342A (es)
KR (1) KR20200096921A (es)
CN (1) CN111565722A (es)
AU (1) AU2018359894A1 (es)
CA (1) CA3080976A1 (es)
IL (1) IL274445A (es)
MX (1) MX2020004837A (es)
WO (1) WO2019090347A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3393475B1 (en) * 2015-12-24 2025-02-05 Corvus Pharmaceuticals, Inc. Ciforadent alone or in combination with atezolizumab for use in treating cancer
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
CN111163780A (zh) 2017-07-18 2020-05-15 诺维逊生物股份有限公司 作为腺苷拮抗剂的杂环化合物
US12174192B2 (en) 2018-07-12 2024-12-24 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
US12116635B2 (en) 2018-07-12 2024-10-15 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
CN113795267A (zh) * 2019-03-12 2021-12-14 艾库斯生物科学有限公司 致癌基因驱动的癌症的治疗
WO2020205527A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
BR112022011235A2 (pt) 2019-12-09 2022-12-13 Twist Bioscience Corp Bibliotecas de variantes de ácido nucleico para receptores de adenosina
CA3176321A1 (en) * 2020-04-22 2021-10-28 Peng Zhang Anti-cd73-anti-pd-1 bispecific antibody and use thereof
KR20230147617A (ko) * 2021-01-21 2023-10-23 트위스트 바이오사이언스 코포레이션 아데노신 수용체에 관한 방법 및 조성물
WO2022166796A1 (zh) * 2021-02-05 2022-08-11 上海齐鲁制药研究中心有限公司 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
EP3207377B1 (en) * 2014-10-15 2024-11-06 Epic Sciences, Inc. Circulating tumor cell diagnostics for therapy targeting pd-l1
EP3393475B1 (en) * 2015-12-24 2025-02-05 Corvus Pharmaceuticals, Inc. Ciforadent alone or in combination with atezolizumab for use in treating cancer
EP3423494A1 (en) * 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies

Also Published As

Publication number Publication date
JP2021502342A (ja) 2021-01-28
AU2018359894A1 (en) 2020-05-21
US20210008206A1 (en) 2021-01-14
CN111565722A (zh) 2020-08-21
WO2019090347A1 (en) 2019-05-09
CA3080976A1 (en) 2019-05-09
KR20200096921A (ko) 2020-08-14
WO2019090347A8 (en) 2019-06-13
EP3706753A1 (en) 2020-09-16
IL274445A (en) 2020-06-30
EP3706753A4 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
MX2025002382A (es) Anticuerpos antagonistas anti-tigit y anti-pd-l1 y usos de los mismos para el tratamiento del cancer
MX2016010080A (es) Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CL2019000821A1 (es) Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
MX2017014375A (es) Moduladores del ccr2.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2017005553A (es) Terapia de combinacion para cancer.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
PE20180260A1 (es) Metodos y kits para tratar la depresion
MX2017015838A (es) Composiciones y metodos para tratar pterigion.
MX367389B (es) Compuestos y sus metodos de empleo.
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
MX391720B (es) Terapia combinada para tratar cáncer.
MX383484B (es) Método para tratar el cáncer.